Evidence map›Paper›PMID 19482602›Full record

ReviewFrontiers in bioscience (Landmark edition)2009

Replication licensing and the DNA damage checkpoint.

Jeanette Gowen Cook

Abstract readReview
In one paragraph

Review in Frontiers in bioscience (Landmark edition), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Inactivation of the Euchromatic Histone-LysineFrontiers in cell and developmental biology · 2021
    Article
  4. DNA Damage Response in Xenopus laevis Cell-Free Extracts.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Prevention of DNA re-replication in eukaryotic cells.Journal of molecular cell biology · 2011
    Review
  14. Article
  15. HDM2 ERKs PCNA.The Journal of cell biology · 2010
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jeanette Gowen CookDepartment of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center Campus Box 7260, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. jean_cook@med.unc.edu

Funding

Replication Licensing and the Cell CycleR01GM083024 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN · 2009 to 2020
$2.9M
Pre-replication complex formation in mammalian cellsK01CA094907 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN · 2003 to 2007
$741k
NCI NIH HHS CA094907NCI NIH HHS K01 CA094907NIGMS NIH HHS R01 GM083024
6 · The paper itself

Abstract

Accurate and timely duplication of chromosomal DNA requires that replication be coordinated with processes that ensure genome integrity. Significant advances in determining how the earliest steps in DNA replication are affected by DNA damage have highlighted some of the mechanisms to establish that coordination. Recent insights have expanded the relationship between the ATM and ATR-dependent checkpoint pathways and the proteins that bind and function at replication origins. These findings suggest that checkpoints and replication are more intimately associated than previously appreciated, even in the absence of exogenous DNA damage. This review summarizes some of these developments.

Indexed as

DNA DamageAnimalsCell CycleCell Cycle ProteinsCheckpoint Kinase 1Cyclin-Dependent KinasesDNA ReplicationHumansModels, BiologicalOrigin Recognition ComplexPhosphorylationProtein KinasesSignal TransductionTranscription FactorsUbiquitinationCell Cycle ProteinsCheckpoint Kinase 1Cyclin-Dependent KinasesOrigin Recognition ComplexProtein KinasesTranscription Factors

Identifiers

PMID19482602
PMCPMC3032801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.